AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
Executive Summary
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.